← Back to Search

Multidisciplinary Care for Rheumatoid Arthritis (MAPPIT-RA Trial)

N/A
Waitlist Available
Led By George A Karpouzas, MD
Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have at least moderate disease activity as indicated by a Clinical Disease Activity Index (CDAI) score >10 and Routine Assessment Patient Index Data (RAPID3) score >2
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, 6 months, 9 months, 12 months
Awards & highlights

MAPPIT-RA Trial Summary

This trial will test a new intervention for socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis to see if it improves remission rates. The intervention is based on a partnership between the patient and the extended healthcare team, and includes things like self-management education and technology-based at-home monitoring of symptoms.

Who is the study for?
This trial is for socioeconomically disadvantaged Hispanic adults in the Greater Los Angeles area with moderate to severe rheumatoid arthritis (RA), as defined by specific clinical scores. Participants must be able to consent, follow the study schedule, and have a phone. Those with other autoimmune conditions, serious joint damage or medical issues that could interfere are excluded.Check my eligibility
What is being tested?
The study tests a comprehensive RA treatment approach combining technology-based symptom monitoring at home, multidisciplinary care from healthcare professionals, nurse-led education and regular follow-ups against standard guideline-based care to see if it improves remission rates after 6 months.See study design
What are the potential side effects?
Since this trial focuses on non-drug interventions like education and monitoring rather than medications, side effects may include discomfort or inconvenience related to frequent communication with healthcare providers and potential privacy concerns regarding symptom reporting.

MAPPIT-RA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My disease is moderately active, with a CDAI score over 10 and a RAPID3 score over 2.

MAPPIT-RA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, 6 months, 9 months, 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, 6 months, 9 months, 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of participants achieving remission based on the Clinical Disease Activity Index at 6 months
Percentage of participants achieving remission based on the Routine Assessment Patient Index Data at 6 months
Secondary outcome measures
Change in Fatigue Visual Analogue Scale (VAS) from baseline
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) from baseline
Change in Pain Visual Analogue Scale (VAS) from baseline
+8 more
Other outcome measures
Brief Illness Perception Questionnaire (BIPQ)
Health Education Impact Questionnaire (heiQ)
Patient Knowledge Questionnaire in Rheumatoid Arthritis (PKQ-RA)
+3 more

MAPPIT-RA Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment4 Interventions
In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
Group II: Control ArmActive Control2 Interventions
Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.

Find a Location

Who is running the clinical trial?

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor
101 Previous Clinical Trials
46,151 Total Patients Enrolled
PfizerIndustry Sponsor
4,567 Previous Clinical Trials
10,911,723 Total Patients Enrolled
102 Trials studying Rheumatoid Arthritis
474,045 Patients Enrolled for Rheumatoid Arthritis
George A Karpouzas, MDPrincipal InvestigatorThe Lundquist Institute at Harbor-UCLA Medical Center

Media Library

Multidisciplinary rheumatologic care Clinical Trial Eligibility Overview. Trial Name: NCT02720874 — N/A
Rheumatoid Arthritis Research Study Groups: Intervention Arm, Control Arm
Rheumatoid Arthritis Clinical Trial 2023: Multidisciplinary rheumatologic care Highlights & Side Effects. Trial Name: NCT02720874 — N/A
Multidisciplinary rheumatologic care 2023 Treatment Timeline for Medical Study. Trial Name: NCT02720874 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment open for the clinical trial at present?

"Based on the information posted to clinicaltrials.gov, this research study is not currently engaging with potential participants. The trial was opened up on January 1st 2023 and had its most recent update on April 5th 2022. While no longer recruiting candidates, there are still 364 other trials actively looking for patients at present."

Answered by AI

What are the projected objectives of this clinical research?

"This research will span 6 months and the primary measurement of success is based on Clinical Disease Activity Index producing remission results. A secondary outcome includes Low Disease Activity at Routine Assessment Patient Index Data (RAPID3). Additionally, Remission as defined by a CDAI score ≤ 2.8., and Health Assessment Questionnaire-Disability Index Change from baseline scores are being tracked to gauge efficacy."

Answered by AI

Who else is applying?

What state do they live in?
Florida
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis
George A Karpouzas, MD 2024. "Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02720874.
All > Rheumatoid Arthritis > Ra
~100 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top